Skip to main content

Contraception clinical trials at UCSF
4 in progress, 3 open to new patients

  • Personal Responsibility Education Program Innovative Strategies: Digital Initiative for Youth

    open to eligible people ages 13-19

    This randomized control trial (RCT) will assess an innovative demonstration project to improve adolescent sexual and reproductive health among highly mobile and marginalized youth in Fresno County, California. The Digital Initiative for Youth intervention combines existing, in-person, group-based, comprehensive sexual health education with wraparound digital technologies. The technological component was designed by Youth+Tech+Health using a "youth-centered" design approach and the intervention is implemented by Fresno Economic Opportunities Commission (Fresno EOC). The University of California, San Francisco is the external evaluator. The RCT will assess health and behavioral outcomes at three time points (baseline, 4 months, 10 months).

    Fresno, California

  • Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

    open to eligible females ages 18-40

    The proposed research study is a Phase IIb, multi-center, single-blind, randomized study of UPA 30 mg, LNG 1.5 mg and LNG 3.0 mg to evaluate EC effectiveness in women with weight ≥ 80 kg who present within 72 hours of unprotected intercourse.

    San Francisco, California and other locations

  • UCSF College Health Study on Contraceptive Training and Education at Community Colleges

    open to eligible females ages 18-25

    The purpose of this study is to measure whether a training and education intervention for clinic staff and young women aged 18-25 on contraceptive methods, including intrauterine devices (IUDs) and the implant, will result in greater contraceptive knowledge and access among students in community colleges.

    San Francisco, California

  • Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

    Sorry, not yet accepting patients

    This is a Phase IIb multicenter, open-label, non-comparative trial of continuous daily oral 10 mg of ulipristal acetate (UPA) to evaluate its contraceptive efficacy as the primary method of contraception.

    San Francisco, California and other locations

Last updated: